{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:16:05Z","timestamp":1740107765191,"version":"3.37.3"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T00:00:00Z","timestamp":1601337600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T00:00:00Z","timestamp":1601337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1007\/s10147-020-01788-6","type":"journal-article","created":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T21:03:14Z","timestamp":1601413394000},"page":"51-58","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Phase II trial of combination treatment with S-1\/cetuximab in patients with platinum-ineligible recurrent and\/or metastatic squamous cell carcinoma of the head and neck"],"prefix":"10.1007","volume":"26","author":[{"given":"Jun","family":"Taguchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2624-4305","authenticated-orcid":false,"given":"Yasushi","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin","family":"Ariga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Goda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihito","family":"Ohhara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rio","family":"Honma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuro","family":"Noguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ichiro","family":"Kinoshita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toraji","family":"Amano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takatsugu","family":"Mizumachi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Kano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miki","family":"Takahara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahisa","family":"Abe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Homma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotoshi","family":"Dosaka-Akita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,9,29]]},"reference":[{"issue":"6","key":"1788_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394\u2013424. https:\/\/doi.org\/10.3322\/caac.21492","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"1788_CR2","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.radonc.2009.04.014","volume":"92","author":"JP Pignon","year":"2009","unstructured":"Pignon JP, le Maitre A, Maillard E et al (2009) Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 92(1):4\u201314. https:\/\/doi.org\/10.1016\/j.radonc.2009.04.014","journal-title":"Radiother Oncol"},{"issue":"19","key":"1788_CR3","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1056\/NEJMoa032641","volume":"350","author":"J Bernier","year":"2004","unstructured":"Bernier J, Domenge C, Ozsahin M et al (2004) Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 350(19):1945\u20131952. https:\/\/doi.org\/10.1056\/NEJMoa032641","journal-title":"N Engl J Med"},{"issue":"19","key":"1788_CR4","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1056\/NEJMoa032646","volume":"350","author":"JS Cooper","year":"2004","unstructured":"Cooper JS, Pajak TF, Forastiere AA et al (2004) Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 350(19):1937\u20131944. https:\/\/doi.org\/10.1056\/NEJMoa032646","journal-title":"N Engl J Med"},{"key":"1788_CR5","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq453","author":"JB Vermorken","year":"2010","unstructured":"Vermorken JB, Specenier P (2010) Optimal treatment for recurrent\/metastatic head and neck cancer. Ann Oncol. https:\/\/doi.org\/10.1093\/annonc\/mdq453","journal-title":"Ann Oncol"},{"key":"1788_CR6","unstructured":"National Comprehensive Cancer Network Head and Neck Cancers (Version 3.2019) https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/head-and-neck_blocks.pdf. Accessed February 23, 2020"},{"issue":"11","key":"1788_CR7","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","volume":"359","author":"JB Vermorken","year":"2008","unstructured":"Vermorken JB, Mesia R, Rivera F et al (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359(11):1116\u20131127. https:\/\/doi.org\/10.1056\/NEJMoa0802656","journal-title":"N Engl J Med"},{"issue":"11","key":"1788_CR8","first-page":"2602","volume":"56","author":"T Shirasaka","year":"1996","unstructured":"Shirasaka T, Nakano K, Takechi T et al (1996) Antitumor activity of 1\u00a0M tegafur-04\u00a0M 5-chloro-2,4-dihydroxypyridine-1\u00a0M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res 56(11):2602\u20132606","journal-title":"Cancer Res"},{"issue":"18","key":"1788_CR9","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1056\/NEJMoa072252","volume":"357","author":"S Sakuramoto","year":"2007","unstructured":"Sakuramoto S, Sasako M, Yamaguchi T et al (2007) Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357(18):1810\u20131820. https:\/\/doi.org\/10.1056\/NEJMoa072252","journal-title":"N Engl J Med"},{"issue":"3","key":"1788_CR10","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S1470-2045(08)70035-4","volume":"9","author":"W Koizumi","year":"2008","unstructured":"Koizumi W, Narahara H, Hara T et al (2008) S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 9(3):215\u2013221. https:\/\/doi.org\/10.1016\/S1470-2045(08)70035-4","journal-title":"Lancet Oncol"},{"issue":"13","key":"1788_CR11","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1016\/S1470-2045(13)70490-X","volume":"14","author":"Y Yamada","year":"2013","unstructured":"Yamada Y, Takahari D, Matsumoto H et al (2013) Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial. Lancet Oncol 14(13):1278\u20131286. https:\/\/doi.org\/10.1016\/S1470-2045(13)70490-X","journal-title":"Lancet Oncol"},{"issue":"9","key":"1788_CR12","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/S1470-2045(10)70181-9","volume":"11","author":"K Muro","year":"2010","unstructured":"Muro K, Boku N, Shimada Y et al (2010) Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2\/3 non-inferiority study (FIRIS study). Lancet Oncol 11(9):853\u2013860. https:\/\/doi.org\/10.1016\/S1470-2045(10)70181-9","journal-title":"Lancet Oncol"},{"issue":"10041","key":"1788_CR13","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/S0140-6736(16)30583-9","volume":"388","author":"K Uesaka","year":"2016","unstructured":"Uesaka K, Boku N, Fukutomi A et al (2016) Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet 388(10041):248\u2013257. https:\/\/doi.org\/10.1016\/S0140-6736(16)30583-9","journal-title":"Lancet"},{"issue":"13","key":"1788_CR14","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1200\/JCO.2012.43.3680","volume":"31","author":"H Ueno","year":"2013","unstructured":"Ueno H, Ioka T, Ikeda M et al (2013) Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J Clin Oncol 31(13):1640\u20131648. https:\/\/doi.org\/10.1200\/JCO.2012.43.3680","journal-title":"J Clin Oncol"},{"issue":"7","key":"1788_CR15","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1093\/annonc\/mdv190","volume":"26","author":"K Kubota","year":"2015","unstructured":"Kubota K, Sakai H, Katakami N et al (2015) A randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese patients with advanced non-small-cell lung cancer: TCOG0701 CATS trial. Ann Oncol 26(7):1401\u20131408. https:\/\/doi.org\/10.1093\/annonc\/mdv190","journal-title":"Ann Oncol"},{"issue":"36","key":"1788_CR16","doi-asserted-by":"publisher","first-page":"5240","DOI":"10.1200\/JCO.2010.31.0326","volume":"28","author":"I Okamoto","year":"2010","unstructured":"Okamoto I, Yoshioka H, Morita S et al (2010) Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer: results of a west Japan oncology group study. J Clin Oncol 28(36):5240\u20135246. https:\/\/doi.org\/10.1200\/JCO.2010.31.0326","journal-title":"J Clin Oncol"},{"issue":"1","key":"1788_CR17","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/S1470-2045(15)00411-8","volume":"17","author":"T Takashima","year":"2016","unstructured":"Takashima T, Mukai H, Hara F et al (2016) Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial. Lancet Oncol 17(1):90\u201398. https:\/\/doi.org\/10.1016\/S1470-2045(15)00411-8","journal-title":"Lancet Oncol"},{"issue":"12","key":"1788_CR18","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1093\/jjco\/hyr147","volume":"41","author":"T Yokota","year":"2011","unstructured":"Yokota T, Onozawa Y, Boku N et al (2011) S-1 monotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck after progression on platinum-based chemotherapy. Jpn J Clin Oncol 41(12):1351\u20131357. https:\/\/doi.org\/10.1093\/jjco\/hyr147","journal-title":"Jpn J Clin Oncol"},{"issue":"6","key":"1788_CR19","doi-asserted-by":"publisher","first-page":"e0198391","DOI":"10.1371\/journal.pone.0198391","volume":"13","author":"A Kubota","year":"2018","unstructured":"Kubota A, Nakatani E, Tsukahara K et al (2018) Adjuvant chemotherapy with S-1 after curative chemoradiotherapy in patients with locoregionally advanced squamous cell carcinoma of the head and neck: reanalysis of the ACTS-HNC study. PLoS ONE 13(6):e0198391. https:\/\/doi.org\/10.1371\/journal.pone.0198391","journal-title":"PLoS ONE"},{"issue":"9","key":"1788_CR20","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1111\/j.1349-7006.2011.02004.x","volume":"102","author":"K Sakata","year":"2011","unstructured":"Sakata K, Someya M, Matsumoto Y et al (2011) Gimeracil, an inhibitor of dihydropyrimidine dehydrogenase, inhibits the early step in homologous recombination. Cancer Sci 102(9):1712\u20131716. https:\/\/doi.org\/10.1111\/j.1349-7006.2011.02004.x","journal-title":"Cancer Sci"},{"issue":"1","key":"1788_CR21","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1093\/annonc\/mdq298","volume":"22","author":"M Tahara","year":"2011","unstructured":"Tahara M, Araki K, Okano S et al (2011) Phase I trial of combination chemotherapy with docetaxel, cisplatin and S-1 (TPS) in patients with locally advanced or recurrent\/metastatic head and neck cancer. Ann Oncol 22(1):175\u2013180. https:\/\/doi.org\/10.1093\/annonc\/mdq298","journal-title":"Ann Oncol"},{"issue":"6","key":"1788_CR22","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1111\/cas.12657","volume":"106","author":"M Tahara","year":"2015","unstructured":"Tahara M, Kiyota N, Mizusawa J et al (2015) Phase II trial of chemoradiotherapy with S-1 plus cisplatin for unresectable locally advanced head and neck cancer (JCOG0706). Cancer Sci 106(6):726\u2013733. https:\/\/doi.org\/10.1111\/cas.12657","journal-title":"Cancer Sci"},{"issue":"4","key":"1788_CR23","doi-asserted-by":"publisher","first-page":"975","DOI":"10.3892\/ijo.2011.1279","volume":"40","author":"K Fukuda","year":"2012","unstructured":"Fukuda K, Saikawa Y, Takahashi M et al (2012) Antitumor effect of cetuximab in combination with S-1 in EGFR-amplified gastric cancer cells. Int J Oncol 40(4):975\u2013982. https:\/\/doi.org\/10.3892\/ijo.2011.1279","journal-title":"Int J Oncol"},{"issue":"5","key":"1788_CR24","doi-asserted-by":"publisher","first-page":"755","DOI":"10.3892\/etm.2012.484","volume":"3","author":"M Nukatsuka","year":"2012","unstructured":"Nukatsuka M, Saito H, Nakagawa F et al (2012) Combination therapy using oral S-1 and targeted agents against human tumor xenografts in nude mice. Exp Ther Med 3(5):755\u2013762. https:\/\/doi.org\/10.3892\/etm.2012.484","journal-title":"Exp Ther Med"},{"issue":"3","key":"1788_CR25","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s00280-016-3109-4","volume":"78","author":"T Takahashi","year":"2016","unstructured":"Takahashi T, Emi Y, Oki E et al (2016) Multicenter phase II study of combination therapy with cetuximab and S-1 in patients with KRAS exon 2 wild-type unresectable colorectal cancer previously treated with irinotecan, oxaliplatin, and fluoropyrimidines (KSCC 0901 study). Cancer Chemother Pharmacol 78(3):585\u2013593. https:\/\/doi.org\/10.1007\/s00280-016-3109-4","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"1788_CR26","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228\u2013247. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"issue":"10","key":"1788_CR27","first-page":"1381","volume":"28","author":"Y Inuyama","year":"2001","unstructured":"Inuyama Y, Kida A, Tsukuda M et al (2001) Late phase II study of S-1 in patients with advanced head and neck cancer. Gan kagaku ryoho Cancer Chemother 28(10):1381\u20131390","journal-title":"Gan kagaku ryoho Cancer Chemother"},{"issue":"6","key":"1788_CR28","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1007\/s00280-014-2459-z","volume":"73","author":"V Saloura","year":"2014","unstructured":"Saloura V, Cohen EE, Licitra L et al (2014) An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neck. Cancer Chemother Pharmacol 73(6):1227\u20131239. https:\/\/doi.org\/10.1007\/s00280-014-2459-z","journal-title":"Cancer Chemother Pharmacol"},{"issue":"24","key":"1788_CR29","doi-asserted-by":"publisher","first-page":"5568","DOI":"10.1200\/JCO.2005.07.119","volume":"23","author":"J Baselga","year":"2005","unstructured":"Baselga J, Trigo JM, Bourhis J et al (2005) Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and\/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 23(24):5568\u20135577. https:\/\/doi.org\/10.1200\/JCO.2005.07.119","journal-title":"J Clin Oncol"},{"issue":"24","key":"1788_CR30","doi-asserted-by":"publisher","first-page":"5578","DOI":"10.1200\/JCO.2005.07.120","volume":"23","author":"RS Herbst","year":"2005","unstructured":"Herbst RS, Arquette M, Shin DM et al (2005) Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 23(24):5578\u20135587. https:\/\/doi.org\/10.1200\/JCO.2005.07.120","journal-title":"J Clin Oncol"},{"issue":"19","key":"1788_CR31","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","volume":"375","author":"RL Ferris","year":"2016","unstructured":"Ferris RL, Blumenschein G Jr, Fayette J et al (2016) Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 375(19):1856\u20131867. https:\/\/doi.org\/10.1056\/NEJMoa1602252","journal-title":"N Engl J Med"},{"issue":"10167","key":"1788_CR32","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/S0140-6736(18)31999-8","volume":"393","author":"EEW Cohen","year":"2019","unstructured":"Cohen EEW, Soulieres D, Le Tourneau C et al (2019) Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet 393(10167):156\u2013167. https:\/\/doi.org\/10.1016\/S0140-6736(18)31999-8","journal-title":"Lancet"},{"key":"1788_CR33","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.lungcan.2017.07.034","volume":"112","author":"G Schvartsman","year":"2017","unstructured":"Schvartsman G, Peng SA, Bis G et al (2017) Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer. Lung Cancer 112:90\u201395. https:\/\/doi.org\/10.1016\/j.lungcan.2017.07.034","journal-title":"Lung Cancer"},{"issue":"2","key":"1788_CR34","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.eururo.2017.08.022","volume":"73","author":"B Szabados","year":"2018","unstructured":"Szabados B, van Dijk N, Tang YZ et al (2018) Response Rate to Chemotherapy After Immune Checkpoint Inhibition in Metastatic Urothelial Cancer. Eur Urol 73(2):149\u2013152. https:\/\/doi.org\/10.1016\/j.eururo.2017.08.022","journal-title":"Eur Urol"},{"key":"1788_CR35","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25154","author":"C Rossi","year":"2018","unstructured":"Rossi C, Gilhodes J, Maerevoet M et al (2018) Efficacy of chemotherapy or chemo-anti-PD-1 combination after failed anti-PD-1 therapy for relapsed and refractory Hodgkin lymphoma: a series from Lysa centers. Am J Hematol. https:\/\/doi.org\/10.1002\/ajh.25154","journal-title":"Am J Hematol"},{"key":"1788_CR36","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.ejca.2019.08.026","volume":"121","author":"K Saleh","year":"2019","unstructured":"Saleh K, Daste A, Martin N et al (2019) Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and\/or metastatic squamous cell carcinoma of the head and neck. Eur J Cancer 121:123\u2013129. https:\/\/doi.org\/10.1016\/j.ejca.2019.08.026","journal-title":"Eur J Cancer"},{"issue":"10212","key":"1788_CR37","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","volume":"394","author":"B Burtness","year":"2019","unstructured":"Burtness B, Harrington KJ, Greil R et al (2019) Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 394(10212):1915\u20131928. https:\/\/doi.org\/10.1016\/S0140-6736(19)32591-7","journal-title":"Lancet"},{"issue":"4","key":"1788_CR38","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1093\/annonc\/mdr367","volume":"23","author":"R Hitt","year":"2012","unstructured":"Hitt R, Irigoyen A, Cortes-Funes H et al (2012) Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and\/or metastatic squamous cell carcinoma of head and neck. Ann Oncol 23(4):1016\u20131022. https:\/\/doi.org\/10.1093\/annonc\/mdr367","journal-title":"Ann Oncol"},{"issue":"16","key":"1788_CR39","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1200\/JCO.2006.06.7447","volume":"25","author":"JB Vermorken","year":"2007","unstructured":"Vermorken JB, Trigo J, Hitt R et al (2007) Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and\/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 25(16):2171\u20132177. https:\/\/doi.org\/10.1200\/JCO.2006.06.7447","journal-title":"J Clin Oncol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-020-01788-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-020-01788-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-020-01788-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T02:16:33Z","timestamp":1659060993000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-020-01788-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,29]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["1788"],"URL":"https:\/\/doi.org\/10.1007\/s10147-020-01788-6","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"type":"print","value":"1341-9625"},{"type":"electronic","value":"1437-7772"}],"subject":[],"published":{"date-parts":[[2020,9,29]]},"assertion":[{"value":"29 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Hirotoshi Dosaka-Akita received scholarship donations from Taiho Pharmaceutical Company. The remaining co-authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}